David Wierz

“Demonstrating comparative value is foundational to meet the clinical, financial, and operational goals in delivering health and care. I integrate work across digital health, payers, health systems, and the life sciences to deploy the strategy that translates value into differentiated models for care delivery, payment, and contracting.”

David J. Wierz joined Discern Health as a Senior Advisor in 2019. His expertise delivers the revenue model and business roadmap for products and services that build sustainable returns in care management, digital health, and life science for early-stage to Fortune 50 companies for US and global markets.

David’s leadership focuses on execution. He builds the evidence demonstrating comparative clinical, financial, and operational gains across providers, manufacturers, payers, and consumers. David applies his knowledge of how policy defines payment and care delivery to create business operations and systems that enhance managing patients in post-acute and long-term care. Central to his work is improving the ability for organizations to meet the inked goals for refining clinical outcomes together with building consumer engagement and financial performance.

Prior to joining Discern, David led US, North American and global operations setting commercial strategy, value and payment in the life sciences (Lifescan, Pfizer, Takada, Baxalta, Novartis Oncology), digital health (Symptom Control, Biosign, Life Navigator) and care delivery (TakeCare, SSM Health). He currently serves as a Health and Digital Health Due Diligence Reviewer and Portfolio Advisor for as Ben Franklin Technology Partners (BFTP) of Southeastern Pennsylvania.

Areas of Expertise

  • Go-to-market strategy, value & payment
  • Integrated care models – post-acute, at-home, chronic
  • Performance-based analytics & contracting


  • iMSA – University of Illinois – In Process
  • MA (ABD) – Wharton Doctoral Program, The University of Pennsylvania
  • AB – The College, The University of Chicago

Honors and Awards

  • Incite Award – Biosimilar Franchise Evaluation – Baxalta

Discern expands Health Economics and Outcomes Research (HEOR) Capabilities For Life Sciences clients

Health economics and outcomes research (HEOR) has long been important for health care market access outside the U.S., but it is increasingly being utilized in the U.S. as part of the movement from vol...
Learn More






Contact Us



Guy D’Andrea Speaks About Innovative Payment Models

Click here to view the VIDEO